Tuberous Sclerosis Complex Tsc clinical trials

Explore recruiting tuberous sclerosis complex tsc clinical trials.

Recruiting tuberous sclerosis complex tsc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Tuberous Sclerosis Complex Tsc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months of age (PROTECT)

Germany, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Treatment with full-spectrum cannabis extract of refractory epilepsy associated with Tuberous Sclerosis Complex (TSC): SPECTRUM

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive Therapy in Children, Adolescents, and Young Adults with Seizures Associated with Tuberous Sclerosis Complex

Spain, Italy, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC OLE)

Germany, Spain, Italy, France, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radiprodil in Patients with Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) Type II.

Spain, Poland, Italy, Netherlands, Belgium

Phase I and Phase II (Integrated)- Other EU CTIS Study details

An open-label, multi-center long-term safety roll-over study in patients with tuberous sclerosis complex (TSC) and refractory seizures who are judged by the Investigator to benefit from continued treatment with everolimus after completion of Study CRAD001M2304 (EXIST-3)

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Tuberous Sclerosis Complex Tsc trials by city

Tuberous Sclerosis Complex Tsc in Toronto Tuberous Sclerosis Complex Tsc in Vancouver Tuberous Sclerosis Complex Tsc in Montreal Tuberous Sclerosis Complex Tsc in Calgary Tuberous Sclerosis Complex Tsc in Edmonton Tuberous Sclerosis Complex Tsc in Ottawa Tuberous Sclerosis Complex Tsc in Winnipeg Tuberous Sclerosis Complex Tsc in Quebec City Tuberous Sclerosis Complex Tsc in Hamilton Tuberous Sclerosis Complex Tsc in Kitchener Tuberous Sclerosis Complex Tsc in London Tuberous Sclerosis Complex Tsc in Halifax Tuberous Sclerosis Complex Tsc in New York Tuberous Sclerosis Complex Tsc in Los Angeles Tuberous Sclerosis Complex Tsc in Chicago Tuberous Sclerosis Complex Tsc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease